Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediniceWAR:ICE -1.65%25 EBIT per Share is zł-0.81 as of Mar. 2026. GuruFocus rates WAR:ICE with a GF Score™ of 25/100 and a GF Value™ of zł0.99 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 685 Medical Devices & Instruments companies, Medinice ranks worse than 68.03% on this metric.
Medinice's EBIT per Share for the
three
months ended in Mar. 2026 was zł-0.13.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł-0.81.
During the past 3 years, the average EBIT per Share Growth Rate was -3.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medinice's EBIT per Share or its related term are showing as below:
WAR:ICE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -77.7 Med: -15 Max: -2.1
Current: -3.8
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Medinice was -2.10% per year. The lowest was -77.70% per year. And the median was -15.00% per year.
WAR:ICE's 3-Year EBIT Growth Rate is ranked worse than 68.03% of 685
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs WAR:ICE: -3.80
Medinice's EBIT for the
three
months ended in Mar. 2026 was zł-1.18 Mil.
Medinice (WAR:ICE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medinice EBIT per Share Related Terms
Medinice EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medinice's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.81
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medinice (WAR:ICE) has a EBIT per Share of zł-0.81 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medinice and its competitors. According to the industry distribution chart, Medinice ranks #466 out of 685 companies in the Medical Devices & Instruments industry, placing it in the top 68%.
Is Medinice's EBIT per Share too high?
Medinice's current EBIT per Share is zł-0.81. Based on the distribution chart, Medinice ranks #466 out of 685 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medinice has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medinice's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medinice ranks #466 out of 685 companies for EBIT per Share. This places Medinice in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medinice and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinice's current EBIT per Share is zł-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinice stock overvalued right now?
Based on GuruFocus' analysis, Medinice (WAR:ICE) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.99, compared to a current price of zł71.60 — trading 7132.3% above its estimated fair value. The current EBIT per Share is zł-0.81. Medinice's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medinice (WAR:ICE), the current EBIT per Share is zł-0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medinice (WAR:ICE) Overvalued in 2026?
Based on GuruFocus' analysis, Medinice stock appears to be overvalued.
The current stock price of zł71.60 is trading 7132.3% above its estimated GF Value™ of zł0.99.
GuruFocus considers Medinice to be Significantly Overvalued.
Key valuation signals for WAR:ICE:
EBIT per Share: zł-0.81
GF Value™: zł0.99 vs. price of zł71.60 (7132.3% above fair value)
No single metric tells the full story. See the WAR:ICE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medinice SA is a Polish company operating in the MedTech industry. The company is engaged in creating, developing and commercializing solutions in the field of medicine, in particular, cardiology and cardio surgery. Its portfolio includes close around 12 projects including CathAIO, an electrode with universal diagnostic, electrophysiological, haemodinamic and biohemic functions and can be used for RF ablation; cryoapplicator, for minimally invasive cardiosurgical cryoablation; Med-iConsole allows to reduce the need to use multiple computer devices during electrophysiological treatment; Minimax and Pacepress.
25GF Score
Get the complete analysis for WAR:ICE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:ICE has been successfully added to your 
